Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
A PHASE3 clinical study on Gastrointestinal Stromal Tumor, this trial is completed. The trial is conducted by European Organisation for Research and Treatment of Cancer - EORTC and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
- Grupo Espanol de Investigacion en Sarcomas
- Italian Sarcoma Group
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbeville, France , Angers, France , Bedford Park, Australia , Besançon, France , Bobigny, France , Bordeaux, France , Boulogne-Billancourt, France , Brest, France , Caen, France , Clermont-Ferrand, France and 31 more locations